03.11.2025 / Deals & Cases

Deal: Wenger Vieli advised TRI Dental Implants on the minority investment by Geistlich Pharma

Wenger Vieli advised TRI Dental Implants, a fast-growing Swiss provider of digital dental implant solutions, on the minority investment by Geistlich Pharma, a world-leading Swiss medtech company in medical regeneration.

Founded and headquartered in Hünenberg (ZG), TRI designs and produces all its products in Switzerland and distributes them to over 50 countries. At the heart of TRI®’s innovation is the matrix®, the world’s first dental implant system without an abutment. By eliminating abutments and enabling prosthetic crowns to be screwed directly onto the implant, TRI® simplifies the implant workflow, saving significant time and cost. Combined with a suite of 10 digital apps, the system empowers clinicians with seamless, fully digital solutions for patient care.

Geistlich and TRI® share a foundation of Swiss quality, innovation, and scientific excellence. While TRI® continues its independent, founder-led path and international expansion, the investment underscores a shared vision on digital technologies to shape a patient-centered workflow in dentistry.

The team was led by Beat Speck (Partner, Corporate/M&A) and included Fabienne Nufer (Associate, Corporate/M&A), Dario Schönbächler (Associate, Corporate/M&A), Andrea Christen (Associate, Notarial Services) and Samuel Pils (Junior Lawyer).